Cardiovascular

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.

Mylan buys branded and generic Arixtra

The $225-million deal will give Mylan one of two generics for the deep vein thrombosis drug.

Novartis may have game-changing drug

Novartis may have game-changing drug

By

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

By

Evolocumab holds the FDA's first filed biologics license application for the class.

GAO tallies cost-effective interventions

GAO tallies cost-effective interventions

By

Half-measures, like diabetes educational materials without a part B, fared poorly.

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

By

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

Study questions HDL medication benefit

A study indicates they may do little to reduce the risk of stroke or heart attack.

Merck stifles ezetimibe criticism

The head of evidence-based medicine at Milan's health authority Alberto Donzelli has pulled down criticism of Merck's cholesterol drug ezetimibe from his website, after the drugmaker sent two cease-and-desist letters.

Study links DPP-IV medication to heart failure, hospitalization

Editorial says risk is small, researchers say it could be clinically relevant.

Diovan competition is coming

Novartis no longer has a lock on the Diovan market: the FDA approved Ranbaxy's generic, which will be made in the US.

Triglycerides, not HDL, may be cardio bad guys

Gene mutations lead researchers to rethink ways to protect the heart.

Statins linked to less exercise, more diabetes

Two studies found two different facets of statin therapy—one found patients moved less a year after starting their regimens, and another that the drugs upped the diabetes risk for some.

Cigna expedites Crestor use

Cigna expedites Crestor use

By

The company signed a deal with AstraZeneca in which high-risk heart disease patients can bypass step therapy and go straight to the branded cholesterol fighter.

Boehringer settles Pradaxa suits

The company is settling around 4,000 cases for around $162,500 apiece.

BI's Pradaxa antidote progresses

The drugmaker is set to start patient testing.

FDA says no to Novartis heart drug

FDA says no to Novartis heart drug

By

Novartis says the FDA wants more serelaxin efficacy data.

GSK heart drug misses endpoint

GlaxoSmithKline announced Tuesday its Phase-III drug from the Human Genome Sciences acquisition failed to hit its primary endpoint.

FDA OKs Merck clot drug

Zontivity (vorapaxar) was approved for patients who have already suffered a heart attack or have arterial blockages in the legs.

Novartis finds Europeans need heart facts

Novartis finds Europeans need heart facts

By

The company's 11-country poll found overall awareness about heart failure to be low. The geographic bloc is in the same bucket as the US in terms of mortality rates.

Novartis announces good heart drug results

Novartis announces good heart drug results

By

The drugmaker said successful results prompted an independent Data Monitoring Committee to recommend stopping the trial. The news follows an uneven week of pipeline drug news.

Analyst gives PCSK9 preview

Analyst gives PCSK9 preview

By

Analyses by Jefferies indicate that although doctors are interested in the experimental anti-cholesterol drugs, CV data will be a critical differentiator.

Hawaii sues BMS, Sanofi over Plavix

The state's attorney general says the drugmakers did not reveal that the drug could have a different impact—if any—on patients with East Asian or Pacific Islander heritage.

Old guidelines boosted Zetia prescriptions

Old guidelines boosted Zetia prescriptions

By

Researchers find that Canada has been a significant contributor to Zetia sales.

Study says fat may not be the villain

Researchers say saturated fat may not cause heart disease, but critics say the study is too narrow.

Eliquis enters the DVT business

Eliquis enters the DVT business

By

The FDA approved the blood drug to prevent deep vein thrombosis and pulmonary embolism among hip- and knee-replacement patients. The approval means BMS and Pfizer may encroach upon the territory of J&J's Xarelto.

Amgen's PSCK9 shows rare disease potential

Amgen's PSCK9 shows rare disease potential

By

The Thousand Oaks, Calif. company says its cholesterol-lowering antibody hit its clinical trial endpoint among rare disease patients.

Takeda admits running bad ads

The company said it used "inappropriate expressions" in promotions of a blood pressure medication.

Roche halts lung drug combo test

Roche said an onartuzumab and Tarceva mix did not help advanced non-small cell lung cancer patients with MET-positive tumors.

Xarelto indication stays as-is

The FDA rejected J&J's expanded indication request a third time.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.